# PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

> **NCT01158300** · PHASE1 · COMPLETED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 28 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** VEGF inhibitor PTC299

## Key facts

- **NCT ID:** NCT01158300
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158300, "PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01158300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*